Back to top

Why C&J Energy Services (CJ) Could Be Positioned for a Slump

Read MoreHide Full Article

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is C&J Energy Services, Inc. (CJ - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in CJ.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen seven estimates moving down in the past 60 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from $2.47 a share two month ago to its current level of $1.15.

Also, for the current quarter, C&J Energy Services has seen six downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to 24 cents a share from 73 cents over the past 60 days.   

The stock also has seen some pretty dismal trading lately, as the share price has dropped 18.4% in the past month.

C&J Energy Services, Inc. Price and Consensus

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Retail – Consumer Electronics industry, you may instead consider a better-ranked stock - Archrock, Inc. (AROC - Free Report) . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Archrock, Inc. (AROC) - free report >>

C&J Energy Services, Inc. (CJ) - free report >>

More from Zacks Tale of the Tape

You May Like